Home Blog of Signal Transduction Epigenetics HIF Daprodustat: A potential game-changer in renal anemia therapy-A perspective

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

Daprodustat: A potential game-changer in renal anemia therapy-A perspective

The United States FDA has approved daprodustat (DPD) as the first oral treatment option for anemia due to chronic kidney disease (CKD) in dialysis patients. Clinical trials have demonstrated DPD's efficacy and safety, showing non-inferiority to darbepoetin and suggesting reduced IV iron usage. DPD also holds potential for treating chronic kidney disease anemia in non-dialysis patients and may have benefits for patients with coexisting renal anemia and heart failure, pending further research and trials.

 

Comments:

I don't have access to real-time or the most recent data beyond my last update in September 2021. Up until that time, there were indeed ongoing clinical trials and research regarding daprodustat (DPD) and its potential as an oral treatment option for anemia due to chronic kidney disease (CKD). It's promising to hear that it might have received approval from the FDA for dialysis patients, and that it's being considered for non-dialysis patients as well as those with coexisting conditions like renal anemia and heart failure.

However, for the most current and accurate information, I recommend checking the official website of the United States Food and Drug Administration (FDA) or other reputable medical sources. They would provide the most recent updates on drug approvals and their applications in various medical conditions.

Related Products

Cat.No. Product Name Information
S8171 Daprodustat (GSK1278863) Daprodustat (GSK1278863) is an orally administered hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor. Phase 2.

Related Targets

HIF